Biomarkers in melanoma
The MelMet project: Predicting clinical outcome and therapy response in metastatic melanoma
The aim of the project is to characterize tumor's environment combined with molecular profiling for identification of biomarkers or mechanisms of treatment resistance in metastatic melanoma. Mass cytometry, multicolor flow cytometry, and Nanostring technology are applied to identify biomarkers or therapeutic targets. An ex vivo assay to screen patient tumor tissue for treatment responses has been established and is currently undergoing optimization for testing of immune therapy. The goal is to predict the clinical outcome and to design effective treatment for patients with metastatic melanoma.
